Isosorbide mononitrate indications and usage: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 4: Line 4:
{{CMG}}; {{AE}} {{PB}}
{{CMG}}; {{AE}} {{PB}}


 
Isosorbide mononitrate extended-release tablets are indicated for the prevention of [[angina pectoris]] due to [[coronary artery disease]]. The onset of action of oral ISMN is not sufficiently rapid for this product to be useful in aborting an acute angina episode.




Revision as of 19:27, 30 January 2014

Isosorbide mononitrate
ISOSORBIDE MONONITRATE tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Description
Clinical Pharmacology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Isosorbide mononitrate extended-release tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral ISMN is not sufficiently rapid for this product to be useful in aborting an acute angina episode.


[1]

References

  1. ↑ "ISOSORBIDE MONONITRATE TABLET [ZYDUS PHARMACEUTICALS (USA) INC.]". Retrieved 30 January 2014.
Retrieved from "https://www.wikidoc.org/index.php?title=Isosorbide_mononitrate_indications_and_usage&oldid=936027"